Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, is reporting on the results of a recent clinical observational study. According to the announcement, the study evaluated the application of Vivos’ recently acquired Preventive Oral Device(R), known as the POD(R), in the treatment and prevention of migraine headaches. In its report, the company noted that the study “demonstrated statistically significant results.” The report noted that 92% of study participants reported their migraine symptoms were completely resolved following completion of treatment, with those results being maintained from 3 to 28 months after treatment began. The study assessed the severity of the migraines by using the validated Migraine Disability Assessment Questionnaire (“MIDAS”). Before treatment, participants reported an average MIDAS score of 23.96 +/- 21.34; following treatment; they reported MIDAS scores of 2.58 +/- 4.87, a reduction of 89.2%. “For the tens of millions of patients right here in the U.S. who suffer from migraines, we believe our new POD treatment option has the potential to be game changer,” said Vivos Therapeutics chair and CEO Kirk Huntsman. “Dentists who are using this technology report migraine resolution in about 9 out of 10 migraine sufferers. Not only can this novel oral appliance technology bring relief from migraines, but it is also FDA cleared to treat patients with TMD, teeth grinding (known as bruxism), and many other conditions related to breathing and sleep disorders. We believe this novel technology’s potential is just starting to be realized, and are working to obtain additional FDA clearances for other chronic and debilitating health conditions. Importantly, we expect this high margin new product line will start contributing to Vivos’ revenue in the second half of this year as we seek to work our way towards cash flow positive operations.”
To view the full press release, visit https://ibn.fm/9LpNZ
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA), Temporomandibular Joint Dysfunction (TMD), headaches, and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 33,000 patients worldwide by more than 1,750 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Patient results will vary. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children, as well as the Preventive Oral Device(R), known as the POD(R), for the treatment of TMD and/or bruxism (unconsciously teeth grinding) and the Vivos Sleep POD(TM), which is a mandibular advancement device for the treatment snoring and mild to moderate obstructive sleep apnea in adults. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
